The global epidemiology of antibiotic-resistant Neisseria gonorrhoeae
Abstract
Antimicrobial-resistant Neisseria gonorrhoeae is an evolving global public health threat that increasingly limits treatment options for one of the world’s most common sexually transmitted infections. This review synthesizes the global epidemiology of antimicrobial resistance in N. gonorrhoeae across phenotypic, genomic, clinical and population-level dimensions. Resistance to agents no longer recommended for empiric treatment is widespread, while azithromycin resistance and reduced susceptibility to extended-spectrum cephalosporins continue to emerge. Resistant lineages, including internationally disseminated ceftriaxone-resistant and extensively drug-resistant strains, highlight the capacity of N. gonorrhoeae to acquire and spread resistance across geographic and genetic backgrounds. However, the global burden remains difficult to quantify because surveillance is uneven, extragenital and asymptomatic infections are underrepresented and susceptibility testing methods and interpretive thresholds vary across settings. Resistance is shaped by antimicrobial exposure, sexual network dynamics, international travel, delayed diagnosis and treatment and structural barriers to sexual healthcare. Opportunities to mitigate resistance include more representative and standardized phenotypic and genomic surveillance; diversified treatment strategies including aetiologic point-of-care diagnostics, rapid resistance-guided therapy and newly available oral agents and strengthened prevention efforts through partner notification and treatment and vaccine development. Coordinated, locally informed implementation of those approaches may help preserve effective treatment and reduce the impact of antimicrobial resistance.
Related
- In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022
- Pathogenicity and virulence of Neisseria gonorrhoeae
- Mucosal ACP subunit vaccine formulated with a small molecule STING agonist drives protective TH1/TH17 responses and serum bactericidal antibodies against Neisseria gonorrhoeae
- In vitro activity of gepotidacin against baseline Neisseria gonorrhoeae phenotypes and genotypes recovered from a clinical trial for uncomplicated urogenital gonorrhea (EAGLE-1)
- One-pot LAMP-CRISPR/Cas12b coupled with nanoparticle-based biosensor for point-of-care test of Neisseria gonorrhoeae
BibTeX
@article{ho2026global,
title = {{The global epidemiology of antibiotic-resistant Neisseria gonorrhoeae}},
author = {Matthew Ho and Paul C Adamson and Jeffrey D Klausner and Lao-Tzu Allan-Blitz},
journal = {JAC-antimicrobial resistance},
year = {2026},
month = nov,
doi = {10.1093/jacamr/dlag245},
url = {https://europepmc.org/article/PMC/PMC13729123},
note = {CC BY},
}
RIS
TY - JOUR
TI - The global epidemiology of antibiotic-resistant Neisseria gonorrhoeae
AU - Matthew Ho
AU - Paul C Adamson
AU - Jeffrey D Klausner
AU - Lao-Tzu Allan-Blitz
PY - 2026
DA - 2026/11/03
JO - JAC-antimicrobial resistance
DO - 10.1093/jacamr/dlag245
UR - https://europepmc.org/article/PMC/PMC13729123
AB - Antimicrobial-resistant Neisseria gonorrhoeae is an evolving global public health threat that increasingly limits treatment options for one of the world’s most common sexually transmitted infections. This review synthesizes the global epidemiology of antimicrobial resistance in N. gonorrhoeae across phenotypic, genomic, clinical and population-level dimensions. Resistance to agents no longer recommended for empiric treatment is widespread, while azithromycin resistance and reduced susceptibility to extended-spectrum cephalosporins continue to emerge. Resistant lineages, including internationally disseminated ceftriaxone-resistant and extensively drug-resistant strains, highlight the capacity of N. gonorrhoeae to acquire and spread resistance across geographic and genetic backgrounds. However, the global burden remains difficult to quantify because surveillance is uneven, extragenital and asymptomatic infections are underrepresented and susceptibility testing methods and interpretive thresholds vary across settings. Resistance is shaped by antimicrobial exposure, sexual network dynamics, international travel, delayed diagnosis and treatment and structural barriers to sexual healthcare. Opportunities to mitigate resistance include more representative and standardized phenotypic and genomic surveillance; diversified treatment strategies including aetiologic point-of-care diagnostics, rapid resistance-guided therapy and newly available oral agents and strengthened prevention efforts through partner notification and treatment and vaccine development. Coordinated, locally informed implementation of those approaches may help preserve effective treatment and reduce the impact of antimicrobial resistance.
SN - 2632-1823
ER -